At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
CX-HA and CSdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ophthalmic Solution in Drye Eye Patients
In Brief
An observational study evaluating CX-HA and CS for Dry Eye Disease (DED). Completed, enrolled 20 participants across 1 site.
Detailed Summary
Data analyses and revision of the DED symptoms. A novel ophthalmic solution containing cross-linked CMC (CX-CMC) and Silk Proteins (SP) has been made available on the market. Both molecules have been widely studied for their viscoelastic and hydrating, and wound healing properties. This new ophthalmic solution is the first on the market formulated with a CX-CMC and SP.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Disease (DED)
CountriesItaly
CollaboratorsSan Giovanni Addolorata Hospital
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartSep 2021
Primary CompletionSep 2022
First PostedSep 2024
TodayJul 2026
First PostedSep 20, 2024
Enrollment StartSep 1, 2021
Primary CompletionSep 1, 2022
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 1.8 years ago
Interventions
CX-HA and CSdevice
Sterile Isotonic ophthalmic solution